

RHEUMATOLOGY REFERRAL FORM

www.albertsons.com/specialtycare • Phone: 877.466.8028 • Fax: 877.466.8040



Patient Information

Patient Name: _____ DOB: _____ Sex: M F
 Phone: _____ Cell Phone: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 ICD-10 Diagnosis Code: _____ Diagnosis: _____
 Allergies (please note reaction): _____ Latex
 Current Medications: (list here or attach a medication list): _____
 Comorbidities: (list here or attach a list): _____

INSURANCE INFORMATION - FAX COPY OF PATIENT'S INSURANCE CARD - BOTH SIDES

Prescription Information

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Actemra (tocilizumab)	162mg/0.9mL Prefilled Syringe	<input type="checkbox"/> Inject 162mg subcutaneously every other week.	28-day supply	
		<input type="checkbox"/> Inject 162mg subcutaneously once a week.		
<input type="checkbox"/> Cimzia (certolizumab)	<input type="checkbox"/> Starter Kit 200mg/mL Prefilled Syringe	<input type="checkbox"/> Loading Dose: Inject 400mg (2 syringes) subcutaneously at weeks 0, 2 and 4.	1 kit (6 syringes)	
	<input type="checkbox"/> 200mg/mL Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 400mg (2 syringes) subcutaneously every 4 weeks. <input type="checkbox"/> Maintenance Dose: Inject 200mg (1 syringe) subcutaneously every 2 weeks.	28-day supply	
<input type="checkbox"/> Cosentyx (secukinumab)	<input type="checkbox"/> 150mg Sensoready Pen	<input type="checkbox"/> Loading Dose: Inject 150mg subcutaneously once weekly at weeks 0, 1, 2, 3, and 4. <input type="checkbox"/> Loading Dose: Inject 300mg (2 injections of 150mg) subcutaneously once weekly at weeks 0, 1, 2, 3, and 4.	5 doses	
	<input type="checkbox"/> 150mg Prefilled Syringe	<input type="checkbox"/> Maintenance Dose: Inject 150mg subcutaneously every 4 weeks. <input type="checkbox"/> Maintenance Dose: Inject 300mg (2 injections of 150mg) subcutaneously every 4 weeks.	28-day supply	
<input type="checkbox"/> Enbrel (etanercept)	<input type="checkbox"/> 50mg/mL Sureclick Auto-injector <input type="checkbox"/> 50mg/mL Prefilled Syringe	<input type="checkbox"/> Inject 50mg subcutaneously once a week.	28-day supply	
	<input type="checkbox"/> 25mg/0.5mL Prefilled Syringe <input type="checkbox"/> 25mg Vial	<input type="checkbox"/> Inject 25mg subcutaneously twice a week.	28-day supply	
<input type="checkbox"/> Humira (adalimumab)	10kg to < 15kg <input type="checkbox"/> 10mg/0.1 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 10mg/0.2 mL Prefilled Syringe	<input type="checkbox"/> Inject 10mg subcutaneously every OTHER week.	28-day supply	
	15kg to < 30kg <input type="checkbox"/> 20mg/0.2 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 20mg/0.4 mL Prefilled Syringe	<input type="checkbox"/> Inject 20mg subcutaneously every OTHER week.		
	≥ 30kg <input type="checkbox"/> 40mg/0.4 mL Citrate-free Pen <input type="checkbox"/> 40mg/0.8 mL Pen <input type="checkbox"/> 40mg/0.4 mL Citrate-free Prefilled Syringe <input type="checkbox"/> 40mg/0.8 mL Prefilled Syringe	<input type="checkbox"/> Inject 40mg subcutaneously every OTHER week. <input type="checkbox"/> Inject 40mg subcutaneously every week.		
<input type="checkbox"/> Kineret (anakinra)	100mg/0.67mL Prefilled Syringe	Inject 100mg subcutaneously every 24 hours.	28-day supply	
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 250mg Vial (IV use only)	<input type="checkbox"/> Loading Dose: Inject _____mg via intravenous infusion at 0, 2 and 4 weeks.	28-day supply	
		<input type="checkbox"/> Inject _____mg via intravenous infusion every 4 weeks.	28-day supply	
<input type="checkbox"/> Orencia (abatacept)	<input type="checkbox"/> 125mg/mL Prefilled Syringe <input type="checkbox"/> 125mg/mL Auto-injector	<input type="checkbox"/> Adults and children ≥ 50 kg: Inject 125mg subcutaneously once weekly.		
	<input type="checkbox"/> 87.5/0.7mL Prefilled Syringe <input type="checkbox"/> 50mg/0.4mL Prefilled Syringe	<input type="checkbox"/> Children ≥ 25 to < 50 kg: Inject 87.5mg subcutaneously once weekly. <input type="checkbox"/> Children 10 to < 25 kg: Inject 50mg subcutaneously once weekly.	28-day supply	

Prescription information continued on next page

MEDICATION	STRENGTH	DIRECTIONS	QUANTITY	REFILLS
<input type="checkbox"/> Otrexup (methotrexate)	<input type="checkbox"/> 7.5mg/0.4mL Auto-injector <input type="checkbox"/> 10mg/0.4mL Auto-injector <input type="checkbox"/> 12.5mg/0.4mL Auto-injector <input type="checkbox"/> 15mg/0.4mL Auto-injector <input type="checkbox"/> 17.5mg/0.4mL Auto-injector <input type="checkbox"/> 20mg/0.4mL Auto-injector <input type="checkbox"/> 22.5mg/0.4mL Auto-injector <input type="checkbox"/> 25mg/0.4mL Auto-injector	Inject one auto-injector subcutaneously once weekly.	28-day supply	
<input type="checkbox"/> Rasuvo (methotrexate)	<input type="checkbox"/> 7.5mg/0.15 Auto-injector <input type="checkbox"/> 10mg/0.2mL Auto-injector <input type="checkbox"/> 12.5mg/0.25mL Auto-injector <input type="checkbox"/> 15mg/0.3mL Auto-injector <input type="checkbox"/> 17.5mg/0.35mL Auto-injector <input type="checkbox"/> 20mg/0.4mL Auto-injector <input type="checkbox"/> 22.5 mg/0.45mL Auto-injector <input type="checkbox"/> 25mg/0.5mL Auto-injector <input type="checkbox"/> 27.5mg/0.55mL Auto-injector <input type="checkbox"/> 30mg/0.6mL Auto-injector	Inject one auto-injector subcutaneously once weekly.	28-day supply	
<input type="checkbox"/> Remicade (infliximab) <input type="checkbox"/> Inflectra (infliximab-dyyb)	100mg Vial	<input type="checkbox"/> Loading Dose: Administer _____mg (at _____mg/kg) intravenously at 0, 2 and 6 weeks.	42-day supply	
		<input type="checkbox"/> Maintenance Dose: Administer _____mg (at _____mg/kg) intravenously every _____weeks.	28-day supply	
<input type="checkbox"/> Simponi (golimumab)	<input type="checkbox"/> 50mg/0.5mL SmartJect Auto-injector <input type="checkbox"/> 50mg/0.5mL Prefilled Syringe	Inject 50mg subcutaneously once monthly.	28-day supply	
<input type="checkbox"/> Taltz (ixekizumab)	<input type="checkbox"/> 80mg/mL Auto-injector <input type="checkbox"/> 80mg/mL Prefilled Syringe	<input type="checkbox"/> Inject 160mg subcutaneously at weeks 2, 4, 6, 8, 10 and 12; then inject 80mg subcutaneously every 4 weeks. <input type="checkbox"/> Inject 160mg subcutaneously once, followed by 80mg subcutaneously every 4 weeks. <input type="checkbox"/> Inject 80mg subcutaneously every 4 weeks.	<input type="checkbox"/> 28-day supply <input type="checkbox"/> 84-day supply	
<input type="checkbox"/> Xeljanz (tofacitinib)	<input type="checkbox"/> 5mg Tablet	<input type="checkbox"/> Take 1 tablet by mouth twice daily. <input type="checkbox"/> Take 1 tablet by mouth once a day (renal/hepatic impairment).	60 30	
<input type="checkbox"/> Xeljanz XR (tofacitinib)	<input type="checkbox"/> 11mg XR Tablet	Take 1 tablet by mouth once daily.	30	
Other Medication Name: _____				

Treatment History: **New to Therapy** **Continuation of Therapy**

Hepatitis B Screening Results: HBsAg: _____ Anti-HBs: _____ Anti-HBc: _____
 If applicable, has treatment been initiated? Yes No
 Tuberculosis Assessment Date: Negative Active TB Latent TB History of active or latent TB
 If history of active or latent TB: _____ Adequate treatment is confirmed: Yes No
 History of Irritable Bowel Disease: Yes No

Prescriber Name: _____
 State License #: _____ DEA #: _____ NPI: _____
 Additional Contact Person Name: _____
 Group or Hospital: _____ Phone: _____
 Fax: _____ Email Address: _____
 Address: _____ City: _____ State: _____ Zip: _____
 Prescriber Signature: _____

Product Substitution Permitted Dispensed as Written Date

The prescriber is to comply with state specific prescription requirements such as e-prescribing, state specific prescription form, fax language, etc. Non-compliance with state specific requirements could result in outreach to the prescriber.

Ship to Patient Ship to Prescriber/Clinic Pick up at Albertsons Companies Pharmacy

Date Medication Needed: _____

Confidentiality Warning: The information contained in this facsimile message is privileged and confidential information intended only for the review and use of the individual or entity to which it is addressed. If the reader of this message is not the intended recipient, you are hereby notified that any disclosure, dissemination, distribution or copying of this communication of the information contained herein is strictly prohibited. If you have received this communication in error, please immediately notify sender by telephone, and destroy the original documents.